Merck & Co., Inc. (MRK) stock analysis

Healthcare · Drug Manufacturers - General

From the 10-K filed 2026-02-24

Business type: Franchise

How it makes money

It generates 49% of sales from one oncology therapy, Keytruda, sold primarily to drug wholesalers, hospitals, and government agencies for cancer treatment.

Profitability is concentrated in the Pharmaceutical segment, which generated $58,142 million in 2025. Keytruda alone accounts for $31,680 million of this, driven by its status as an anti-PD-1 therapy approved for dozens of indications including lung, gastric, and biliary tract cancers.

Beyond direct sales, it earns alliance revenue from partners like AstraZeneca and Eisai, representing a share of profits from products like Lynparza and Lenvima. The Animal Health segment provides a $6,354 million secondary stream, selling vaccines and digitally connected identification products to livestock producers and veterinarians.

What protects it: the moat

It relies on composition-of-matter patents to block biosimilar competition for Keytruda until 2028, while using Keytruda Qlex to extend the brand's subcutaneous utility.

Market exclusivity is the primary barrier to entry, specifically the primary compound patent for Keytruda which is expected to prevent biosimilar competition until December 2028. To defend this position, it is transitioning patients to Keytruda Qlex, a fixed combination with berahyaluronidase alfa that allows for subcutaneous administration.

In the U.S. vaccine market, it maintains a unique position as the only manufacturer of the MMRV vaccine ProQuad and the varicella vaccine Varivax, benefiting from established CDC recommendations and the Vaccines for Children program.

What growth costs

It funds approximately 80 Phase 3 studies to diversify its pipeline into immuno-oncology and tissue targeting to offset upcoming patent expirations.

Maintaining and growing earnings requires heavy reinvestment in high-risk clinical trials and business development. It currently manages roughly 80 Phase 3 programs across oncology, cardiometabolic, and infectious disease categories to prepare for a decade-long investment cycle where failures can occur even after significant spending.

Capital is also deployed for acquisitions, such as the purchase of Verona Pharma to obtain the COPD treatment Ohtuvayre, and a $10 billion share repurchase plan to return value as older products like Januvia face revenue declines.

What could damage it

The expiration of U.S. market exclusivity for Januvia and Janumet in May 2026 will cause a loss of nearly all sales for those products.

A specific causal chain of patent expiration and mandatory government price setting threatens to impair earnings. Januvia and Janumet will lose exclusivity in May 2026, followed by Janumet XR in July 2026, leading to a rapid and significant loss of nearly all U.S. revenue for these diabetes treatments.

Further impairment stems from the Inflation Reduction Act and the Most-Favored-Nation Agreement, which creates a price ceiling for key products by referencing international prices and mandating affordable direct-to-patient programs for eligible U.S. patients.

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

More on MRK

Other companies in Drug Manufacturers - General